Background Although immunomodulators have established benefit against the new
coronavirus disease (COVID-19) in general, it is uncertain whether such agents improve …

Background Immunomodulatory therapy has been extensively studied in randomized
clinical trials for the treatment of patients hospitalized for COVID-19 with inconsistent …

Introduction Many immunomodulators have been studied in clinical trials for the treatment of
coronavirus disease 2019 (COVID-19). However, data identifying the most effective and …

The emergency state caused by COVID-19 saw the use of immunomodulators despite the
absence of robust research. To date, the results of relatively few randomized controlled trials …

The coronavirus disease (COVID-19) pandemic has triggered precipitous entry of multiple
novel therapeutic candidates into clinical trials often without control groups, randomization …

With the onset of the global pandemic in 2020 of Severe Acute Respiratory Syndrome
Coronavirus-2 (SARS-CoV-2), there has been increasing research activity around certain …

Because coronavirus disease 2019 (COVID-19) became a dominant factor in our daily lives,
we have learned a tremendous amount about it through both study and shared experience …

Background: Whilst there is literature on the impact of SARS viruses in the severely
immunosuppressed, less is known about the link between routine immunosuppressant use …

Background While immunosuppression poses a theoretical increase in the risk of COVID‐
19, the nature of this relationship is yet to be ascertained. Aims To determine whether …

Objectives To determine if a specific immunomodulatory intervention reduces progression of
COVID-19-related disease to organ failure or death, compared to standard of care (SoC) …